Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

JNJ 101.13 +0.31 (0.31%)
price chart
Johnson & Johnson Prostate Cancer Drug Impresses
A new study shows that Johnson & Johnson's prostate cancer pill Zytiga dramatically slows the progression of the disease in men who are not yet sick enough to start chemotherapy.
Johnson & Johnson Latest Company To Break Away From ALEC
Johnson & Johnson is the latest company to break away from the American Legislative Exchange Council (ALEC). On June 12, Johnson & Johnson announced it would stop funding the group that has pushed states to pass voter ID and stand-your-ground ...
Johnson & Johnson Should Split Up Says Goldman
Johnson & Johnson should split into three companies, which could value health-care conglomerate at $76 a share, up more than 20% from current price of $62, Goldman Sachs says.
Johnson and Johnson's Synthes Deal Revives Foreign Tax Debate
After receiving regulatory clearance for its $19.7 billion acquisition of Swiss medical device maker Synthes, Johnson & Johnson says the mega-deal will add to earnings per share after previously forecasting dilution: All with the help of bankers ...
Johnson & Johnson Announces Completion of Synthes Acquisition  PR Newswire (press release)
Johnson & Johnson's Favorable Ratings: Does The Market Prefer Trademarks ...
Analysts are starting to like Johnson & Johnson again. (Disclaimer: I have now exhausted my knowledge of markets.) What drives the value of companies these days, brand power (trademarks) or brain power (patents)?
Johnson & Johnson diabetes drug tops older therapies in studies
An experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than Merck & Co's Januvia and an older common treatment, glimepiride, according to data from a pair of late stage clinical trials.
Johnson & Johnson a Top Ranked SAFE Dividend Stock With 3.7% Yield
Johnson & Johnson (NYSE: JNJ) has been named to the Dividend Channel ”S.A.F.E. 25” list, signifying a stock with above-average ”DividendRank” statistics including a strong 3.7% yield, as well as a superb track record of at least two decades of dividend ...
Johnson & Johnson Receives U.S. Regulatory Clearance for Synthes ...
NEW BRUNSWICK, N.J., June 12, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received U.S.
Johnson & Johnson now expects Synthes deal to boost profit  Reuters
Johnson & Johnson: Synthes deal closes Thursday  BusinessWeek
Johnson & Johnson wins US approval to buy Synthes
Johnson & Johnson will sell its system for surgically treating serious wrist fractures, and related assets, to Biomet Inc LVBHAB.
Johnson & Johnson plans $600 million charge linked to Risperdal sales
Johnson & Johnson said on Friday it expects to take a special charge of about $600 million in the second quarter to bolster reserves for a potential settlement of civil lawsuits related to how it marketed schizophrenia treatment Risperdal and other drugs.
Risperdal litigation costs growing for Johnson & Johnson  Philadelphia Inquirer (blog)
Johnson & Johnson to pay $2.2B to settle Risperdal probe (report)  Bizjournals.com (blog)